In this meta-analysis, we combined and analysed the data of six updated RCTs that looked into the efficacy of tirzepatide (5, 10 and 15 mg) once weekly against placebo or GLP-1 RAs in adults with obesity or overweight. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.